Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.70 |
| ▸ | CNR2 | P34972 | 1/20 | 0.70 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.70 |
| ▸ | TUBB | P07437 | 2/20 | 0.70 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.70 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.70 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.70 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.70 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.70 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.70 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.70 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.70 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.70 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.70 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.70 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.70 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 14/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075354 | 1.00 | CNR1 (0.70) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7080421 | 0.99 | ESR1 (0.69) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7075664 | 0.95 | ESR1 (0.74) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7075631 | 0.95 | ESR1 (0.74) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL5026252 | 0.95 | CNR1 (0.78) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7075381 | 0.94 | ESR1 (0.72) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL30619806 | 0.93 | ESR1 (0.63) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL11547223 | 0.93 | ESR1 (0.63) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL30619809 | 0.93 | ESR1 (0.64) | CNR1CNR2TUBB4ATUBBTUBA3C | |
| SCHEMBL11555604 | 0.93 | ESR1 (0.63) | CNR1CNR2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117085143-A | PROTACs nano blocking agent for estrogen receptor and preparation method and application thereof | 郑州大学 | 2023-11-21 | — | — | CN | claimed |
| EP-0920863-B1 | The use of 2-Aryl-3-aroylbenzo(b)thiophenes for the treatment of estrogen deprivation syndrome | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | claimed |
| US-6156786-A | ANTIESTROGENS | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | claimed |
| EP-0920863-A1 | 2-Aryl-3-aroylbenzo(b)thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| CN-118356429-A | Fostate-CLIPTAC degradation system and application thereof in preparation of medicines | 杭州医学院 | 2024-07-19 | — | — | CN | disclosed |
| CN-117085143-A | PROTACs nano blocking agent for estrogen receptor and preparation method and application thereof | 郑州大学 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023212599-A2 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ENDOTARGET INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20220079931-A1 | ESTROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| EP-0816360-A1 | Benzothiophene compounds, intermediates, processes, and methods of use | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0766559-A4 | CANNABINOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0766559-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5596106-A | ARYL-BENZO(B)THIOPHENE OR BENZO(B)FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0723537-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1995010513-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | CNR1 4034/4885CNR2 4293/4885TUBB4A 2378/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | CNR1 4081/4885CNR2 4383/4885TUBB4A 2419/4885 |
| US-20220079931-A1 | ESTROGEN RECEPTOR PROTEIN DEGRADERS | ESR1, ESR2, ESRRA | CNR1 740/4885CNR2 1701/4885TUBB4A 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.